CXCR4 and B-cell chronic lymphocytic leukemia: VUN401-Fc has been shown to specifically target CXCR4, block interaction with the receptor and it is ligand CXCL12, and induce NK cell mediated ADCC.31,32 Current standard first-line therapy for CLL includes rituximab, a monoclonal antibody targeting CD20.